HK1064056A1 - An aqueous pharmaceutical preparation of cilostazol for parenteral use - Google Patents

An aqueous pharmaceutical preparation of cilostazol for parenteral use

Info

Publication number
HK1064056A1
HK1064056A1 HK04106926A HK04106926A HK1064056A1 HK 1064056 A1 HK1064056 A1 HK 1064056A1 HK 04106926 A HK04106926 A HK 04106926A HK 04106926 A HK04106926 A HK 04106926A HK 1064056 A1 HK1064056 A1 HK 1064056A1
Authority
HK
Hong Kong
Prior art keywords
cilostazol
pharmaceutical preparation
aqueous pharmaceutical
parenteral use
parenteral
Prior art date
Application number
HK04106926A
Other languages
English (en)
Inventor
Fujio Inoue
Keiichi Kawakami
Shinya Nagayasu
Hideshi Okamoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1064056A1 publication Critical patent/HK1064056A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04106926A 2001-06-13 2004-09-13 An aqueous pharmaceutical preparation of cilostazol for parenteral use HK1064056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001179239 2001-06-13
JP2002127065A JP2003063965A (ja) 2001-06-13 2002-04-26 注射用シロスタゾール水性製剤
PCT/JP2002/005705 WO2002102383A1 (fr) 2001-06-13 2002-06-07 Preparation de cilostazol aqueuse pour injections

Publications (1)

Publication Number Publication Date
HK1064056A1 true HK1064056A1 (en) 2005-01-21

Family

ID=26616861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106926A HK1064056A1 (en) 2001-06-13 2004-09-13 An aqueous pharmaceutical preparation of cilostazol for parenteral use

Country Status (12)

Country Link
US (1) US20040209843A1 (zh)
EP (1) EP1396266A1 (zh)
JP (1) JP2003063965A (zh)
KR (1) KR100720886B1 (zh)
CN (1) CN1223347C (zh)
AR (1) AR034370A1 (zh)
AU (1) AU2002306329B2 (zh)
BR (1) BR0210293A (zh)
CA (1) CA2443466A1 (zh)
HK (1) HK1064056A1 (zh)
MX (1) MXPA03011480A (zh)
WO (1) WO2002102383A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
KR100667367B1 (ko) * 2005-05-10 2007-01-10 충남대학교산학협력단 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US20110092456A1 (en) * 2009-10-19 2011-04-21 Yochai Birnbaum Methods of increasing cAMP levels and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
KR101648740B1 (ko) * 2014-09-04 2016-08-17 경상대학교산학협력단 실로스타졸을 유효성분으로 포함하는 독소루비신에 의한 심부전 또는 확장성 심근병증의 예방용 약학 조성물
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA3004362C (en) * 2015-11-06 2022-10-04 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20220100927A (ko) * 2019-11-22 2022-07-18 실파 메디케어 리미티드 우르소데옥시콜린산의 주입가능한 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
AU3954799A (en) * 1998-05-29 1999-12-20 Janssen Pharmaceutica N.V. Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments
EP1143796A4 (en) * 1999-01-21 2002-03-20 Bristol Myers Squibb Co RAS-FARNESYLTRANSFERASE AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXPROPYL-BETA-CYCLODEXTRIN INHIBITOR COMPLEX AND METHOD
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Also Published As

Publication number Publication date
BR0210293A (pt) 2004-07-13
MXPA03011480A (es) 2004-03-18
CN1223347C (zh) 2005-10-19
CA2443466A1 (en) 2002-12-27
AR034370A1 (es) 2004-02-18
US20040209843A1 (en) 2004-10-21
JP2003063965A (ja) 2003-03-05
WO2002102383A1 (fr) 2002-12-27
KR100720886B1 (ko) 2007-05-22
EP1396266A1 (en) 2004-03-10
AU2002306329B2 (en) 2006-11-30
KR20040005995A (ko) 2004-01-16
CN1505513A (zh) 2004-06-16

Similar Documents

Publication Publication Date Title
HK1064056A1 (en) An aqueous pharmaceutical preparation of cilostazol for parenteral use
HK1208446A1 (zh) 的衍生物
HK1064035A1 (en) Pharmaceutical salts of 1-phenyl-3-dimethylamino-propane compounds
PL363507A1 (en) Pharmaceutical uses of bisphosphonates
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
GB0102342D0 (en) Pharmaceutical formulation
HK1068812A1 (en) Drug preparations
HK1089170A1 (en) Processes for the preparation of 1-[(benzoimidazole-1yl)quinolin-8-yl] piperidin-4-ylamine derivatives
GB0118689D0 (en) Pharmaceutical formulation
AU2002306329A1 (en) Aqueous cilostazol preparation for injection
PL366432A1 (en) Pharmaceutical formulation
GB0101225D0 (en) Pharmaceutical compounds
GB0101227D0 (en) Pharmaceutical compounds
IL162385A0 (en) Process for the preparation of echinocandin derivatives
GB0127832D0 (en) Method for the preparation of pharmaceutical nanosuspensions
PL366559A1 (en) Pediatric formulation of gatifloxacin
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
HRP20040671A2 (en) Imidazoquinoline derivatives
IL158312A (en) Use of pyridoindolone derivatives for preparing anticancer medicines
GB0128138D0 (en) Pharmaceutical use
GB0104749D0 (en) Pharmaceutical formulation
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions
HU0104616D0 (en) Winoscreen-curtain for eliminating of aqueous vapour
IL175282A0 (en) Preparation of pharmaceutical salts of [1,4]-bipiperidine
GB0109520D0 (en) Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090607